PI
KYMR icon

PEAK6 Investments’s Kymera Therapeutics KYMR Stock Holding History

PEAK6 Investments’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$710K Buy
15,000
+2,000
+15% +$88.3K ﹤0.01% 2107
2024
Q2 		$388K Buy
+13,000
New +$450K ﹤0.01% 2389

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

PEAK6 Investments's KYMR Position: Q3 2024 in Review

PEAK6 Investments increased its Kymera Therapeutics (KYMR) stake by 15% in Q3 2024, buying an estimated $88.3K and bringing the position to 15,000 shares worth $710K. The position accounts for ﹤0.01% of the portfolio, ranked #2107.

PEAK6 Investments first reported a position in KYMR in Q2 2024 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold KYMR as of Q3 2024.

  • PEAK6 Investments held 15,000 shares of Kymera Therapeutics worth $710K as of Q3 2024.
  • PEAK6 Investments bought 2,000 Kymera Therapeutics shares in Q3 2024, an estimated $88.3K.
  • Kymera Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2107 holding.
  • PEAK6 Investments first reported a position in Kymera Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.